Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.4/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 54.4; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.3/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 54.1; sample size: 90.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.3; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 61.2; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.2/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 56.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 78.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.1/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 68.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.0/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 60.2; sample size: 90.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 67.3; sample size: 40.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.0/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 52.3; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.8/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 59.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.7/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 95.9; sample size: 60.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 58.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 68.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 50.2; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.5/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 47.5; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 50.0; sample size: 70.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.4/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 52.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 68.9; sample size: 30.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 56.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
